Recent data have suggested that the suppression of PDCD1 could limit tauopathy-related neurodegeneration, while recent in vivo trials have revealed that the microbiota plays a role in the PD-1/PD-L1 pathway and exhibits immunomodulatory properties mediated by anti-PD1 molecules [122,123]. The gene discussed is PDCD1; the disease is tauopathy.